Flagship Pioneering, the bioplatform innovation company, today announced the launch of Apriori Bio, a health security company aimed at providing humanity with variant-proof protection against rapidly evolving viruses. Founded in 2020, Apriori has developed Octavia™, a unique biology-informed AI platform that can infer the full landscape of potential variants for a given virus. Using Octavia, Apriori can define the antibody repertoire that most broadly protects against current and future variants of a virus, enabling the development of variant-proof vaccines and antibody drugs. Flagship's initial commitment to Apriori is $50 million.

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, Octavia, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants.